Skip to main content

Table 1 The clinical features of hepatocellular carcinoma patients in model cohort and validation cohort

From: Comprehensive bioinformatics analysis reveals potential lncRNA biomarkers for overall survival in patients with hepatocellular carcinoma: an on-line individual risk calculator based on TCGA cohort

  Model group (n = 348) Validation cohort (n = 348) P value
Death [n (%)] 130 (37.4) 123 (35.3) 0.582
Survival time (mean ± SD, month) 28.0 ± 23.7 26.6 ± 22.6 0.439
Age (mean ± SD, year) 59.5 ± 13.4 59.6 ± 13.4 0.569
Gender (male/female) 236/112 236/112 1.0
AJCC stage (IV/III/II/I/NA) 4/80/79/164/21 7/70/67/182/22 0.226
AJCC PT (T4/T3/T2/T1/NA) 14/74/87/171/2 10/71/75/192/0 0.163
AJCC PN (N3/N2/N1/N0/NA) 100/3/245/0 117/3/228/0 0.165
AJCC PM (MX/M1/M0/NA) 96/4/248/0 103/7/238/0 0.392
Radiation treatment adjuvant (yes/no/NA) 4/130/114 5/225/118 0.631
Pharmaceutical adjuvant (yes/no/NA) 15/215/118 12/213/123 0.592
Ablation embolization (yes/no/NA) 13/219/116 18/210/120 0.328
  1. Continuous variables were compared by using t-test or Mann–Whitney U test as appropriate; categorical variables were compared by using Chi-squared test or Fisher’s exact test as appropriate
  2. NA missing data, SD standard deviation, AJCC American Joint Committee on Cancer